Kidney damage: The Tipline for 21 February 2019

The snow has started to melt and federal offices in Washington, DC, are back open. Today, we dig into the Federal Trade Commission’s approval of a merger between two kidney treatment companies, as well as dissents from both Democratic commissioners who think the deal could damage competition in the market for dialysis machines. As it's nearly the end of the week, we’re also indulging in some antitrust news about wine and medical weed.

Unlock unlimited access to all Global Competition Review content